Top 5 Stocks to Buy Now
→ The Treasury just bought its own debt (From Golden Portfolio) (Ad)tc pixel Free SXTC Stock Alerts

China SXT Pharmaceuticals (SXTC) Competitors

China SXT Pharmaceuticals logo
$2.54 +0.06 (+2.42%)
Closing price 04:00 PM Eastern
Extended Trading
$2.54 0.00 (-0.16%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SXTC vs. IRD, UPB, NVCT, AMRN, and ABEO

Should you buy China SXT Pharmaceuticals stock or one of its competitors? MarketBeat compares China SXT Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with China SXT Pharmaceuticals include Opus Genetics (IRD), Upstream Bio (UPB), Nuvectis Pharma (NVCT), Amarin (AMRN), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical products" industry.

How does China SXT Pharmaceuticals compare to Opus Genetics?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

China SXT Pharmaceuticals has higher earnings, but lower revenue than Opus Genetics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.74M55.79-$3.30MN/AN/A
Opus Genetics$14.20M21.57-$49.59M-$1.33N/A

China SXT Pharmaceuticals has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

In the previous week, Opus Genetics had 4 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 4 mentions for Opus Genetics and 0 mentions for China SXT Pharmaceuticals. Opus Genetics' average media sentiment score of 0.17 beat China SXT Pharmaceuticals' score of 0.00 indicating that Opus Genetics is being referred to more favorably in the news media.

Company Overall Sentiment
China SXT Pharmaceuticals Neutral
Opus Genetics Neutral

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

China SXT Pharmaceuticals has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. China SXT Pharmaceuticals' return on equity of 0.00% beat Opus Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
Opus Genetics -892.36%-338.88%-191.21%

Opus Genetics has a consensus target price of $10.77, suggesting a potential upside of 190.28%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than China SXT Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Opus Genetics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.94

Summary

Opus Genetics beats China SXT Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

China SXT Pharmaceuticals has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. China SXT Pharmaceuticals' return on equity of 0.00% beat Upstream Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Upstream Bio-4,718.96% -43.82% -42.27%
China SXT Pharmaceuticals N/A N/A N/A

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 16.5% of Upstream Bio shares are held by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

China SXT Pharmaceuticals has lower revenue, but higher earnings than Upstream Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Upstream Bio$2.85M121.54-$143.44M-$2.91N/A
China SXT Pharmaceuticals$1.74M55.79-$3.30MN/AN/A

In the previous week, Upstream Bio had 3 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 3 mentions for Upstream Bio and 0 mentions for China SXT Pharmaceuticals. Upstream Bio's average media sentiment score of 0.52 beat China SXT Pharmaceuticals' score of 0.00 indicating that Upstream Bio is being referred to more favorably in the media.

Company Overall Sentiment
Upstream Bio Positive
China SXT Pharmaceuticals Neutral

Upstream Bio presently has a consensus price target of $33.17, suggesting a potential upside of 421.08%. Given Upstream Bio's stronger consensus rating and higher probable upside, analysts clearly believe Upstream Bio is more favorable than China SXT Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Upstream Bio
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Upstream Bio has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

Summary

Upstream Bio beats China SXT Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Nuvectis Pharma?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

China SXT Pharmaceuticals has higher revenue and earnings than Nuvectis Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.74M55.79-$3.30MN/AN/A
Nuvectis PharmaN/AN/A-$26.44M-$1.31N/A

Nuvectis Pharma has a consensus target price of $39.00, suggesting a potential upside of 59.31%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Nuvectis Pharma is more favorable than China SXT Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Nuvectis Pharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Nuvectis Pharma had 9 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 9 mentions for Nuvectis Pharma and 0 mentions for China SXT Pharmaceuticals. Nuvectis Pharma's average media sentiment score of 0.75 beat China SXT Pharmaceuticals' score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
China SXT Pharmaceuticals Neutral
Nuvectis Pharma Positive

China SXT Pharmaceuticals has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

China SXT Pharmaceuticals' return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
Nuvectis Pharma N/A -161.00%-98.88%

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Nuvectis Pharma beats China SXT Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Amarin?

Amarin (NASDAQ:AMRN) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Amarin currently has a consensus target price of $12.00, suggesting a potential downside of 26.95%. Given Amarin's stronger consensus rating and higher probable upside, equities analysts plainly believe Amarin is more favorable than China SXT Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amarin
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.00
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

China SXT Pharmaceuticals has lower revenue, but higher earnings than Amarin.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$213.65M1.61-$38.80M-$0.65N/A
China SXT Pharmaceuticals$1.74M55.79-$3.30MN/AN/A

Amarin has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

China SXT Pharmaceuticals has a net margin of 0.00% compared to Amarin's net margin of -15.51%. China SXT Pharmaceuticals' return on equity of 0.00% beat Amarin's return on equity.

Company Net Margins Return on Equity Return on Assets
Amarin-15.51% -2.99% -2.07%
China SXT Pharmaceuticals N/A N/A N/A

22.3% of Amarin shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Amarin had 16 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 16 mentions for Amarin and 0 mentions for China SXT Pharmaceuticals. Amarin's average media sentiment score of 0.56 beat China SXT Pharmaceuticals' score of 0.00 indicating that Amarin is being referred to more favorably in the media.

Company Overall Sentiment
Amarin Positive
China SXT Pharmaceuticals Neutral

Summary

Amarin beats China SXT Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Abeona Therapeutics?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

China SXT Pharmaceuticals has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

In the previous week, Abeona Therapeutics' average media sentiment score of 1.90 beat China SXT Pharmaceuticals' score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
China SXT Pharmaceuticals Neutral
Abeona Therapeutics Very Positive

China SXT Pharmaceuticals' return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
Abeona Therapeutics N/A -53.98%-38.52%

Abeona Therapeutics has higher revenue and earnings than China SXT Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.74M55.79-$3.30MN/AN/A
Abeona Therapeutics$5.82M55.03$71.18M$0.975.79

Abeona Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 238.08%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than China SXT Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Abeona Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Abeona Therapeutics beats China SXT Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get China SXT Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SXTC vs. The Competition

Export
MetricChina SXT PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$94.78M$2.99B$6.54B$12.32B
Dividend YieldN/A1.78%2.68%5.88%
P/E RatioN/A18.6525.3923.96
Price / Sales55.79341.96530.17107.90
Price / CashN/A56.6445.2953.76
Price / Book0.004.1410.766.41
Net Income-$3.30M$64.45M$3.56B$337.14M
7 Day Performance14.41%1.34%1.37%-0.48%
1 Month Performance57.76%0.95%0.81%0.49%
1 Year Performance-99.06%24.33%30.53%28.16%

China SXT Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SXTC
China SXT Pharmaceuticals
0.7553 of 5 stars		$2.54
+2.4%		N/A-99.1%$94.78M$1.74MN/A90
IRD
Opus Genetics
2.8441 of 5 stars		$4.06
+4.1%		$10.67
+162.7%		+350.2%$335.22M$11.98MN/A14
UPB
Upstream Bio
2.0792 of 5 stars		$6.15
+3.9%		$33.17
+439.3%		-41.0%$334.68M$2.85MN/A38
NVCT
Nuvectis Pharma
2.2564 of 5 stars		$12.59
+5.4%		$13.00
+3.3%		+120.5%$334.01MN/AN/A8
AMRN
Amarin
1.1736 of 5 stars		$15.77
+4.0%		$12.00
-23.9%		+26.7%$330.68M$216.76MN/A360

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SXTC) was last updated on 6/24/2026 by MarketBeat.com Staff.
From Our Partners
Firm That Predicted 2008, 2020, 2022: Right Now Looks Worse
The firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...
TradeSmith | Sponsoredtc pixel
The Treasury just bought its own debt
On April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...
Golden Portfolio | Sponsoredtc pixel
Elon’s message for America
Elon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...
Stansberry Research | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Elon Is Quietly Doubling Down on This Bizarre Asset
Yahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...
Brownstone Research | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel